Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Feb;44(2):279-285.
doi: 10.1111/liv.15777. Epub 2023 Dec 15.

The role of HBIG in real life for patients undergoing liver transplantation due to HDV-related cirrhosis

Sergio Rodríguez-Tajes  1   2 , María García-Eliz  2   3 , Arantxa Caballero Marcos  4 , Isabel Campos-Varela  5 , Alba Cachero Ros  6 , Carmelo Loinaz  7 , Miguel Á Gómez Bravo  8 , Manuel Rodríguez-Perálvarez  2   9 , Emilio Fabrega  10 , María L González Diéguez  11 , Carmen Vinaixa  2   3 , José M Pascasio  2   8 , Inmaculada Fernández Vázquez  7 , Carme Baliellas  6 , Lluis Castells  2   5 , Magdalena Salcedo  4 , Martín Prieto  2   3 , Gonzalo Crespo  1   2 , Sabela Lens  1   2 , Xavier Forns  1   2
Affiliations

The role of HBIG in real life for patients undergoing liver transplantation due to HDV-related cirrhosis

Sergio Rodríguez-Tajes et al. Liver Int. 2024 Feb.

Abstract

Recommended post-liver transplant (LT) prophylaxis in patients with hepatitis delta includes a nucleos(t)ide analogue (NA) and anti-hepatitis B immunoglobulin (HBIG) indefinitely. We analysed the use of HBIG in real-life clinical practice and its impact on HBV/HDV recurrence in 174 HDV-related LT patients from 10 Spanish liver transplant centres (1988-2018). Median post-LT follow-up was 7.8 (2.3-15.1) years and patient survival at 5 years was 90%. Most patients (97%) received HBIG in the immediate post-LT, but only 42% were on HBIG at the last control. Among those discontinuing HBIG, the median time on treatment was 18 (7-52) months. Post-LT HBsAg+ was detected in 16 (9%) patients and HBV-DNA in 12 (7%). Despite HBsAg positivity, HDV recurrence was reported only in three patients (1.7%), all of whom were not receiving NA and had discontinued HBIG. Our data suggest that a finite HBIG prophylaxis in HDV-LT is feasible, especially if high-barrier NAs are used.

Keywords: hepatitis B; hepatitis B immunoglobulin; hepatitis delta; liver transplantation.

PubMed Disclaimer

References

REFERENCES

    1. Hughes SA, Wedemeyer H, Harrison PM. Hepatitis delta virus. Lancet. 2011;378(9785):73-85.
    1. Buti M, Homs M, Rodriguez-Frias F, et al. Clinical outcome of acute and chronic hepatitis delta over time: a long-term follow-up study. J Viral Hepat. 2011;18(6):434-442.
    1. Romeo R, Del Ninno E, Rumi M, et al. A 28-year study of the course of hepatitis δ infection: a risk factor for cirrhosis and hepatocellular carcinoma. Gastroenterology. 2009;136(5):1629-1638.
    1. Fattovich G, Giustina G, Christensen E, et al. Influence of hepatitis delta virus infection on morbidity and mortality in compensated cirrhosis type B. The European Concerted Action on Viral Hepatitis (Eurohep). Gut. 2000;46(3):420-426.
    1. Dietz-Fricke C, Tacke F, Zöllner C, et al. Treating hepatitis D with bulevirtide-real-world experience from 114 patients. JHEP Rep. 2023;5(4):100686.

LinkOut - more resources